TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04412122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping+Breathing Exercise
Description: In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention was performed to reduce pain in the control group.
Study: NCT03340259

Intervention type: PROCEDURE
Intervention: Exposure(s) of interest: enterostomy
Description: Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
Study: NCT02997410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ozone)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental treatment with occlusal splint
Study: NCT02693288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia
Description: Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
Study: NCT02848625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
Study: NCT03359447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily Ferrous Sulfate
Description: Drops
Study: NCT04006301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74699157
Description: Participants will receive JNJ-74699157 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74699157
Description: Participants will receive JNJ-74699157 orally.
Study: NCT00703352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone (coated tablet) 50mg daily during 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone (coated tablet) 50mg daily during 12 months.
Study: NCT02196610

Intervention type: OTHER
Intervention: Applanation tonometry
Description: Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.

Intervention type: OTHER
Intervention: Applanation tonometry
Description: Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
Study: NCT03936166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CRN01941 Oral Solution
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN01941 Oral Solution
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN01941 Oral Solution
Description: Investigational drug
Study: NCT02158104

Intervention type: PROCEDURE
Intervention: Deep dry needling
Study: NCT01665066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;
Study: NCT03936166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CRN01941 Oral Capsule
Description: Investigational drug
Study: NCT01665066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study: NCT03936166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN01941 Oral Capsule
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN01941 Oral Capsule
Description: Investigational drug
Study: NCT01665066

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study: NCT01873053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-34B
Description: Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-34B
Description: Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01144260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bafetinib
Description: 250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
Study: NCT02526862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allevyn Thin®
Description: Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Askina Transorbent Border®
Description: Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linovera®
Description: Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
Study: NCT03173911

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Application of Elastic Bandage Therapy by the Therapy Taping method
Study: NCT01665066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study: NCT03173911

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Application of Elastic Bandage Therapy by the Therapy Taping method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Application of Elastic Bandage Therapy by the Therapy Taping method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Application of Elastic Bandage Therapy by the Therapy Taping method
Study: NCT01665066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free
Study: NCT03936166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Solution
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Solution
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo
Study: NCT01862341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANMUM In-Shape Nutritional Milk Powder for Active Mothers
Study: NCT03166579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
Study: NCT04236440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B2)
Description: 80 μg BAY2586116 (nasal spray)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B3)
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B3)
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
Study: NCT01243684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTI - Diffusor Tensor Imaging
Description: Radiology intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTI - Diffusor Tensor Imaging
Description: Radiology intervention
Study: NCT04236440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (C)
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (C)
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
Study: NCT04290143

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment (colored tap water)
Description: Patients will be treated with colored tap water for 20 minutes.
Study: NCT04015310

Intervention type: DEVICE
Intervention: Quantitative Multi parametric MRI and enhanced MRCP
Description: Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
Study: NCT03677583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duckweed
Description: various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinach
Description: various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
Study: NCT01665066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study: NCT04730245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phosphate enema, oral rifaximin and polyethylene glycol
Description: Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
Study: NCT00796055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-547
Description: Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
Study: NCT04208750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision R-800 Phoropter
Description: Refraction utilizing the Vision R-800 Phoropter with resulting glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vision R-800 Phoropter
Description: Refraction utilizing the Vision R-800 Phoropter with resulting glasses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Phoropter
Description: Refraction utilizing the standard phoropter with resulting glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Phoropter
Description: Refraction utilizing the standard phoropter with resulting glasses
Study: NCT01555697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study: NCT05927597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS1007
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS1007
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS1007
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS1007
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS1007
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets.
Study: NCT02466841

Intervention type: PROCEDURE
Intervention: Cubital tunnel release
Description: Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
Study: NCT00527020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
Study: NCT03936166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo
Study: NCT00527020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine Lozenges will be supplied as 4 milligrams lozenges.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine Lozenges will be supplied as 4 milligrams lozenges.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine Lozenges will be supplied as 4 milligrams lozenges.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine Lozenges will be supplied as 4 milligrams lozenges.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine Lozenges will be supplied as 4 milligrams lozenges.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to the subjects.
Study: NCT01056120

Intervention type: DEVICE
Intervention: Pro Kinetic Energy bare metal stent
Description: PCI
Study: NCT01536704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine lozenge in two formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine lozenge in two formulations
Study: NCT03990103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: 80-120 mg/day, PO, D1-14, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: 80-120 mg/day, PO, D1-14, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 200 mg, IP, D1, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2, IV, D1, every 21 days